Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026. The event will feature two sessions to accommodate global audiences and will include a real-time, interactive demonstration led by CEO Panna Sharma. The demonstration will showcase the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.
The withZeta.ai platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. Lantern Pharma is a clinical-stage precision oncology company that leverages AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The live demo represents a significant milestone for Lantern as withZeta.ai is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. This event provides an opportunity for researchers, investors, and industry stakeholders to see firsthand how the platform can integrate diverse data types to generate insights that may shorten drug development cycles. For more details, the full press release is available at https://ibn.fm/wzevl.
The demonstration comes at a time when AI-driven drug discovery is gaining traction as a way to reduce the high costs and long timelines associated with traditional pharmaceutical R&D. By showcasing a multi-agentic AI system that can autonomously handle complex workflows, Lantern aims to position itself at the forefront of this trend. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. Investors can find the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN.
